Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer
International Journal of Colorectal Disease · 2025
DOI: 10.1007/s00384-024-04792-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2025. Verfasst von Dilimire Abuliezi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, West China Hospital of Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Ultrasonography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science and Technology Planning Project of Sichuan Province, China.
Abstract (Originalsprache)
Purpose
This study aimed to explore a combined transrectal ultrasound (TRUS) and radiomics model for predicting tumor regression grade (TRG) after neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer (LARC).
Methods
Among 190 patients with LARC, 53 belonged to GRG and 137 to PRG. Eight TRUS parameters were identified as statistically significant ( P < 0.05) for distinguishing between the groups, including PSV pre , LD post , TD post , CEUS-IG post , LD change rate, TD change rate, RI change rate, and CEUS-IG downgrade. The accuracies of these individual parameters in predicting TRG were 0.42, 0.62, 0.56, 0.68, 0.67, 0.70, 0.63, and 0.71, respectively. The AUC values were 0.596, 0.597, 0.630, 0.752, 0.686, 0.660, 0.650, and 0.666, respectively. The multi-parameter ultrasonic logistic regression (MPU-LR) model achieved an accuracy of 0.816 and an AUC of 0.851 (95% CI: [0.792–0.909]). The optimal pre- and post-treatment radiomics models were RF (Mean-PCA-RFE-6) and AE (Zscore-PCA-RFE-12), with accuracies of 0.563 and 0.596 and AUCs of 0.601 (95% CI: [0.561–0.641]) and 0.662 (95% CI: [0.630–0.694]), respectively. The combined model (US-RAD pre -RAD post ) showed the highest predictive power with accuracy and AUC of 0.863 and 0.913.
Conclusions
The combined model based on TRUS and radiomics demonstrated remarkable predictive capability for TRG after NCRT. It serves as a precision tool for assessing NCRT response in patients with LARC, impacting treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Ultrasound, West China Hospital of Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
- Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, 37#Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
- Department of Medical Ultrasound, West China Hospital of Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China. zhuanghua@wchscu.cn.
Förderung
- The Science and Technology Planning Project of Sichuan Province, China
Zitieren
APA
Abuliezi, D., She, Y., Liao, Z., Luo, Y., Yang, Y., Huang, Q., Tao, A., & Zhuang, H. (2025). Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-024-04792-8
Vancouver
Abuliezi D, She Y, Liao Z, Luo Y, Yang Y, Huang Q, et al. Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer. International Journal of Colorectal Disease. 2025. doi:10.1007/s00384-024-04792-8
BibTeX
@article{Abuliezi2025,
author = {Abuliezi, Dilimire and She, Yufen and Liao, Zhongfan and Luo, Yuan and Yang, Yin and Huang, Qin and Tao, Anqi and Zhuang, Hua},
title = {Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer},
journal = {International Journal of Colorectal Disease},
year = {2025},
doi = {10.1007/s00384-024-04792-8}
}
EUVIMED